Breast Cancer Biopsy Surface Antigens
Biopsies . | Dx . | SLT-R . | Combined Ber-EP4/M38 . | LMWK . |
---|---|---|---|---|
BC-1 | IDC | +/++ | +/++ | ND |
BC-2 | IDC | ++ | ++ | ND |
BC-3 | IDC | + | − | ND |
BC-4 | ILC | ++ | − | ND |
BC-5 | IDC | + | − | + |
BC-6 | ILC | + | − | + |
BC-7 | IDC | ++ | ++ | + |
BC-8 | IDC | − | − | ND |
BC-9 | ILC | − | − | ND |
BC-10 | IDC | +++ | +++ | ND |
Biopsies . | Dx . | SLT-R . | Combined Ber-EP4/M38 . | LMWK . |
---|---|---|---|---|
BC-1 | IDC | +/++ | +/++ | ND |
BC-2 | IDC | ++ | ++ | ND |
BC-3 | IDC | + | − | ND |
BC-4 | ILC | ++ | − | ND |
BC-5 | IDC | + | − | + |
BC-6 | ILC | + | − | + |
BC-7 | IDC | ++ | ++ | + |
BC-8 | IDC | − | − | ND |
BC-9 | ILC | − | − | ND |
BC-10 | IDC | +++ | +++ | ND |
Flow cytometric analysis of primary based cancer biopsy material for surface expression of SLT-R and combined Ber-EP4/M38. Also shown are results for immunohistochemical analysis of cytospins for LMWK. Expression of surface antigen in terms of percentage of cells staining positively for a marker: defined as negative or − (0% to 14%), weak or + (15% to 40%), intermediate or ++ (41% to 70%), and strong or +++ (71% to 100%).
Abbreviations: Dx, morphological diagnosis; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LMWK, low molecular weight keratins detected by immunohistochemistry, expression is defined as negative (−) or positive (+) only; ND, not determined.